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Abstract: Increasing evidence witnesses that cancer metabolism alterations represent a critical hallmark for many 
types of human tumors. There is a strong need to understand and dissect the molecular mechanisms underlying 
cancer metabolism to envisage specific biomarkers and underpin critical molecular components that might represent 
novel therapeutic targets. One challenge, that is the focus of this review, is the reprogramming of the altered 
metabolism of a cancer cell toward that of un-transformed cell. The anti-hyperglicemic agent, metformin has 
proven to be effective in reprogramming the metabolism of cancer cells even from those subpopulations endowed 
with cancer stem like features and very high chemoresistenace to conventional anticancer treatments. A functional 
interplay involving selective modulation of microRNAs (miRNAs) takes place along the anticancer metabolic effects 
exerted by metformin. The implications of this interplay will be also discussed in this review.
Keywords: Diabetes; cancer; microRNA (miRNA); therapy; chemoprevention; metabolism
Submitted Apr 08, 2014. Accepted for publication May 26, 2014.
doi: 10.3978/j.issn.2305-5839.2014.06.03
View this article at: http://dx.doi.org/10.3978/j.issn.2305-5839.2014.06.03
Introduction
The anti-hyperglycemic agent, metformin, is a synthetic 
dimethylbiguanide compound designed to reduce the 
side effects of Galega officinalis (the French lilac), rich in 
guanidine, which was usually prescribed to treat symptoms 
of diabetes up until the early 1930s in France (1).
Today, metformin is a world wide prescribed agent for 
treating patients with type II diabetes (T2D) due to its 
ability to suppress hepatic gluconeogenesis and reduce 
blood glucose levels (2). Metformin is also prescribed for 
treating some metabolic disorders such as insulin resistance 
and for women affected by polycystic ovary syndrome 
(PCOS), one of the most common female endocrine 
disorders.
Although the molecular mechanisms underlying 
metformin action remains a topic of much debate, 
the activation of the energy sensing enzyme AMP-
activated protein kinase (AMPK), a key enzyme of energy 
homeostasis, has emerged as playing a crucial role in this 
process. Indeed, metfomin-mediated AMPK activation leads 
to the modulation of targets that restore energy homeostasis 
by enhancing glucose uptake into the skeletal muscle (3) 
and by inhibiting hepatic gluconeogenesis (4).
Interestingly, diabetic patients treated with metformin 
had a significantly reduced risk of cancer compared to other 
patients treated with other hypoglycemic therapies (5). 
Bowker et al. found a positive correlation between metformin 
assumption and cancer prevention. T2D patients who use 
metformin have a lower cancer-related mortality incidence 
compared with insulin users (6).
There is a huge amount of epidemiological evidence 
relating to new molecular findings on the role of 
metabolism in cancer development and progression. Cancer 
cells, in fact, utilize glucose for glycolitic ATP generation 
and macromolecule synthesis (7), while metformin 
activity passes through a direct modulation of metabolic 
homeostasis keepers, such as AMPK. This condition 
impairs glycolysis and glucose uptake, mimicking starvation, 
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thus promoting apoptosis in tumor cells. 
Moreover, in vivo combination therapy using metformin 
together with different chemotherapeutic agents, such as 
carboplatin, cisplatin, doxorubicin and paclitaxel, has been 
shown to increase the citotoxicity (8). Metformin has also 
shown to enhance radiation response in vivo (9).
Based on molecular and retrospective epidemiological 
evidence, numerous trials have been designed to test 
metformin not only as an anti-neoplastic agent in patients 
with established cancer, but also as a chemopreventive agent 
in preventing tumor formation (10).
There are several ongoing studies that are attempting 
to determine the role of metformin as a chemopreventive 
agent. These studies include phase I, phase II and phase III 
trials (clinicaltrials.gov.).
Here, we review the anticancer activity of metformin 
focusing on its anticancer metabolic effects that occur 
through a direct modulation of metabolic genes and 
microRNAs (miRNAs). We first describe metformin’s 
anticancer molecular mechanisms of action and its role in 
the inhibition of tumor growth and proliferation. We then 
provide insights into metabolic reprogramming of cancer 
cells mediated by metformin through the modulation of 
non-coding RNAs, emphasizing the crucial role of miRNA-
33a in the metabolism of breast cancer cells.
Metformin anticancer mechanisms of action
Although the underlying mechanisms of metformin action 
are still being elucidated, several studies highlight its 
influence on the cellular energy balance. 
Metformin diffuses into the cells through the organic 
cation transporters (OCTs) (11). OCT1 null mice show a 
reduction in hepatic metformin uptake, which is the main 
target of this drug (12). Once in the citosol, metformim 
induces an increase in the cellular AMP:ATP ratio 
inhibiting complex I of mitochondrial respiratory chain 
(13,14). Consequently, ATP depletion is checked by the 
AMPK γ subunit that binds specifically to AMP. This 
causes conformational changes that allosterically activate 
the enzyme and inhibit dephosphorylation on Thr-172 
within the activation loop of the catalytic α subunit (15,16). 
A subsequent phosphorylation of the catalytic α subunit on 
thr-172 residue is required to activate AMPK (17).
Metformin requires liver kinase B1 (LKB1), a tumor 
suppressor gene, to phosphorylate the α subunit of AMPK 
at Thr-172 and to activate the enzyme (17). This contributes 
to maintain plasma glucose and insulin homeostasis.
Once activated, AMPK regulates not only a pool of 
substrates which represents the key enzymes in the catabolic 
pathways and inhibits ATP-consuming anabolic pathways, 
but also enzymes involved in cell cycle and protein 
metabolism.
As described by Hardie et al., LKB1 and AMPK pathway 
functions act as a cellular energy-sensing checkpoint that 
controls cell growth and proliferation. This depends also 
from the availability of fuel supplies (18).
However, there is evidence suggesting that metformin 
acts via an AMPK-independent way of action. Kalender 
et al. showed that metformin can enhance glucose uptake 
in rat skeletal muscle cells and inhibits mTOR signaling 
independent of AMPK (19). Foretz et al. found that 
metformin inhibited liver glucose synthesis independent of 
LKB1 or AMPK status (20). 
Interestingly, the ataxia telangiectasia mutated (ATM) 
gene, a tumor suppressor gene involved in DNA repair and 
cell cycle control, was discovered to activate AMPK through 
LKB1 dependent and independent pathways (21,22).
Both AMPK-dependent and independent pathways 
have been proposed to mediate the anticancer effects of 
metformin treatment. In the following paragraphs we will 
discuss both metformin’s mechanisms of action.
AMPK-dependent mechanisms of action 
As mentioned above, AMPK activation induces the 
inhibition of anabolic processes, consequently activating also 
catabolic processes in order to restore energy homeostasis. 
Two canonical anabolic processes such as lipogenesis and 
cholesterol synthesis are inhibited by metformin through 
AMPK activation (23,24) (Figure 1). Indeed, tumors such as 
breast, colon, prostate and ovarian cancer are characterized by 
a high rate of lipid metabolism. High expression of fatty acid 
synthase (FAS) is a predictor of recurrence in stage I breast 
carcinoma (25), lung carcinoma (26), endometrial carcinoma 
patients (27). This is correlated with a worse prognosis in 
breast carcinomas (28) and ovarian carcinomas (29). Recently, 
Cantoria et al., have shown that metformin induced growth 
arrest of pancreatic tumor cells through a direct inhibition of 
fatty acid synthesis (30). 
Not only lipid synthesis but also cholesterol synthesis 
plays a pivotal role in cancer cell metabolism. Based on 
this set of evidence, metformin induces a shift in lipid and 
cholesterol metabolism that could deprive pre-malignant 
and malignant cells of several substrates important for their 
growth and proliferation. 
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Indeed, activated AMPK impairs FAS and 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase, thus, reducing 
the consumption of ATP. As a result, macromolecules are 
oxidated to produce new ATP molecules, in order to restore 
the ATP levels reduced by the metformin action.
Several evidences indicate that metformin impinges on 
other pathways. One of these is the phosphatidylinositiol 
3-kinase (PI3K)/AKT/mammalian target of rapamycin 
(mTOR) signaling pathway. It is a conserved signaling 
pathway that tunes cell growth, survival and metabolism. 
Growth factors and nutrients stimuli impinge this pathway 
to sustain cell growth and proliferation [85]. Unfortunately, a 
series of aberrations of this signaling axis promotes a number 
of malignant and non-malignant diseases. Indeed, the PI3K/
Akt/mTOR pathways are often deregulated in a large number 
of tumors and represent an emerging strategy for tumor 
treatment. Nowadays, anti mTOR therapies are an alternative 
strategy for renal cell carcinomas and breast cancer treatment. 
Oncogenic activity of mTOR passes, largely, through the 
constitutive activation of the protein synthesis pathway. In 
fact, mTOR directly activates two important targets involved 
in this process, such as S6 kinase (S6K) and translation 
initiation factor 4E binding protein 1 (4EBP1) (31). 
Interestingly, mTORC1, one of the two functional complexes 
on mTOR, is negatively regulated by AMPK (Figure 1). 
AMPK, in fact, directly phosphorylates and inhibits 
mTORC1 binding partner Raptor and, indirectly, modulates 
the activity of tuberous sclerosis complex 2 (TSC2), which 
together with TSC1 form a tumor suppressor complex that 
inhibits mTOR (32-34).
Metformin has been reported to inhibit  tumor 
progression of renal cell carcinoma (35), proliferation of 
bladder cancer cells in vitro and in vivo (36) and skin tumor 
promotion in overweight and obese mice (37) by inhibiting 
mTOR activity through AMPK modulation. In addition, 
osteosarcoma cell lines treated with metformin exhibited a 
significant cell growth reduction in comparison to untreated 
cells. This effect appeared to be correlated with an increased 
expression of AMPK and the consequence inhibition of 
mTOR downstream targets (38). 
The metabolic reprogramming induced by metformin 
passes, also, through p53 activation. Metformin selectively 
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Figure 1 Metformin anticancer activities 
Figure 1 Metformin anticancer activities: schematic representation of the pathways that are perturbed by metformin activities. AMPK 
plays a crucial role in the metformin anticancer activities by modulating proteins involved in several biological processes such as protein 
translation (mTOR), cell proliferation (p53-p21 axis, mTOR), fatty acid synthesis (FASN, ACACA), aromatase (CRTC2) and sterol 
synthesis (HMG-CoA). Metformin impacts on cell proliferation through the modulation of the insulin signalling. Metformin regulates 
DNA damage and inflammatory responses impinging on ATM/CHK2 and TNFα activities respectively.
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impairs p53-deficient tumor cell growth unlike those 
carrying wild type p53 proteins are no longer able to 
reprogram their metabolism and become apoptotic (39) 
(Figure 1). 
Moreover, activation of AMPK stimulates cell cycle 
arrest through the p53/p21 axis (40). Indeed, AMPK 
phosphorylates p53 on serine 15 (40). This phosphorylation 
is not sufficient for p53 activation (41,42), however, mutation 
of p53 on serine 18 impairs the ability of AMPK to induce 
cell cycle arrest (40). He and colleagues demonstrated that 
AMPK-mediated phosphorylation of human MDMX on 
Ser342 leads to an enhanced association between MDMX 
and 14-3-3. This event inhibits p53 ubiquitylation and 
markedly stabilizes and activates p53 (43). 
Recently, metformin was reported to inhibit melanoma 
cell line proliferation through the activation ofAMPK/p53 
signaling (44).
The oncogene c-myc plays an important role during 
the premalignant and malignant stages of tumor growth, 
which makes it an ideal prevention and therapeutic target. 
Akinyeke et al. showed that c-myc protein levels were 
reduced by metformin treatment in prostate cancer cell 
lines and in prostate cancer mouse models. They addressed 
to the AMPK pathway, the down regulation of c-myc (45); 
however, we reported that the metformin-mediated-c-myc 
inhibition is a consequence of the up regulation of miR-33a 
in breast cancer cell lines (46). 
Interestingly, metformin-induced activation of AMPK 
inhibited angiogenesis through the VEGF-dependent 
activation of ERK1/2. The inhibition of AMPK activity, in 
fact, abrogated this event (47) (Figure 1).
Metformin impaired aromatase expression in primary 
human breast adipose stromal cells. This occurred via 
AMPK and resulted in the inhibition of CREB regulated 
transcription co-activator 2 (CRTC2) (48) (Figure 1). 
Altogether these findings might suggest that, metformin 
could be used in the treatment for hormone-dependent 
post-menopausal breast carcinomas.
AMPK-independent mechanisms of action 
Although, AMPK represents a key target in the metformin 
anticancer mechanism of action, there is evidence showing 
that metformin exert its action, also, in an AMPK-
independent way. Metformin has been shown to inhibit 
the PI3K/Akt/mTOR signaling pathway in an AMPK 
independent way. Metformin modulated the activity of 
mTOR, in lung tissues, by decreasing activation of insulin 
like growth factor receptor 1 (IGFR1) and Akt (49). Other 
evidence highlighted the role of Rag GTPase in modulating 
mTOR activity as a consequence of metformin treatment (19) 
(Figure 1). 
Metformin has been reported to exert anti-proliferative 
activity on glioblastoma cells through inhibiting the Akt 
pathway (50) or by inhibiting mTOR via an increase in 
PRAS40-RAPTOR binding efficiency, an association known 
to increase during stressful conditions (51). 
Hyperandrogenemia is promoted by an aberrant 
synergistic action between luteinizing hormone (LH) and 
estrogen produced by granulose cells under insulin like 
growth factor 1 (IGF1) stimulation (52). The increase of 
insulin like growth factor binding protein 1 (IGFBP1), 
mediated by metformin, has been reported to limit the 
binding between IGF1 and their receptors (IGF1R) and 
consequently also the production of androgen (Figure 1). 
Subsequently, metformin treatment may synergize with 
common anti-androgen therapies, which are usually 
prescribed for metastatic prostate cancer treatment (53). 
Moreover, high levels of IGF-1 impaired chemotherapy-
induced apoptosis by activating the PI3K/Akt pathway. 
Inhibition of IGF1R sensitized small cell lung cancer cell 
lines to the cytotoxic effects of etoposide and carboplatin 
combined treatment (54).
Quinn et al. found that metformin decreased lung 
tumorigenesis in liver IGF-I-deficient (LID) mice. 
The authors suggested that metformin directly inhibits 
circulating growth factors and local receptor tyrosine kinase 
(RTK) signaling in an AMPK/IGF-I independent way (55). 
Metformin was,  a lso,  found to reduce chronic 
inflammatory response by inhibiting the tumor necrosis 
factor alpha (TNFα) production in human monocytes (56). 
In addition, it was demonstrated that metformin blocks the 
production of endogenous reactive oxygen species (ROS) 
by interfering the mitochondrial complex I activity (57) 
(Figure 1). Metformin modulates the activity of checkpoint 
homolog kinase 2 (CHK2) which results in an increased 
sensitivity of cancer cells against DNA damage (58,59) 
(Figure 1). Recently, Do and colleagues proposed the Raf-
ERK-Nrf2 axis and the subsequent down regulation of 
heme oxygenase-1 to explain a new AMPK-independent 
metformin anticancer mechanism of action (60).
Ma et al. demonstrated that cancer cell response to 
metformin was influenced by the K-Ras status (61). In fact, 
they showed that metformin induced apoptosis in the K-Ras 
mutant tumors, derived from A549 and PANC 1, but not in 
the K-Ras wild type tumor, derived from A431 cells (61).
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MicroRNA, metabolism and cancer 
Over the last few years several evidences have shown that 
metformin can exert its anticancer effects through miRNAs 
modulation. miRNAs are a family of small non-coding 
RNAs of about 20-25 nucleotides in length, evolutionarily 
conserved across species. They regulate gene expression at 
the post-transcriptional level. Many miRNAs (~50%) are 
in close proximity to other miRNAs, suggesting that they 
are transcribed as clusters from a single polycistronic unit 
(TU) (62-65). MiRNAs can be generated from both non-
coding TUs and protein-coding TUs. In particular, ~40% 
of miRNA loci are present in the intronic region of non-
coding transcripts, whereas ~10% are placed in the exonic 
region of non-coding TUs. miRNAs in protein-coding TUs 
are usually found in intronic regions (~40%) but a minor 
fraction of them (~10%) can also be present in exonic/
intronic regions, depending on the alternative splicing 
patterns (66).
RNA Polymerase II is the enzyme that transcribes 
miRNA genes in a 170 bp primary transcript (pri-miRNA), 
containing both a 5’cap and a poly (A) tail, folding into a 
hairpin-shaped structure (67). The first step of miRNA 
maturation is a cleavage at the stem of the hairpin performed 
by the “Microprocessor complex”. This large nuclear 
complex contains two proteins, Drosha and DGCR8, 
conserved only in animals. These two proteins recognize 
and crop the stem structure releasing a small hairpin (~70 nt) 
termed “pre-miRNA” (68). After nuclear cropping, pre-
miRNAs are exported to the cytosol by exportin 5, a 
member of the nuclear transport receptor family (69,70). In 
the cytoplasm, the hairpin precursors are cleaved by Dicer, 
a highly conserved RNAse III endonuclease, thus releasing 
~22 nt miRNA duplexes (71,72). One of the two strands, the 
mature miRNA, is loaded onto an Ago protein to generate 
the effector complex of the miRNA pathway, the RISC (or 
miRISC). Once in the miRISC, partial pairing between a 
miRNA and the 3'UTR of target mRNA occurs, resulting 
in repression of protein translation or in case of complete 
pairing, in mRNA degradation (73). 
MiRNAs are key regulators of many biological processes, 
such as cell proliferation, differentiation, apoptosis, stress 
response and angiogenesis due to their ability to bind 3'UTR 
of multiple target mRNAs. This is why any deregulation 
of miRNAs expression can contribute to diverse human 
pathologies, including cancer (74). Indeed, miRNAs behave 
either as oncogenes or tumor suppressor genes thereby 
promoting or inhibiting cancer progression.
Growing evidences have highlighted the role of 
miRNAs as master regulators of metabolic processes, such 
as lipid and cholesterol-synthesis. As mentioned before, 
perturbation of these processes represents an important 
step in tumor development, but also a strategic opportunity 
to block the activity of specific miRNAs by using synthetic 
antagomirs. MiRNA-122 family are the most abundant 
miRNAs in the liver and modulate cholesterol and lipid 
metabolism. Interestingly, the antisense targeting of miR-
122 resulted in a decrease of plasma cholesterol levels in 
mouse models (75,76). This occurs through the indirect 
modulation of genes involved in cholesterol biosynthesis, 
such as 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(Hmgcs1), 3-hydroxy-3-methylglutaryl-CoA reductase 
(Hmgcr) and 7-dehydrocholesterol reductase (Dhcr7) (76). 
Similarly, the miR-33 family represents a potential target 
for the treatment of metabolic disorders. MiR-33a and 
miR-33b are intronic miRNAs that are encoded together 
with their host genes, the sterol-regulatory element-binding 
protein 1 (Srebp1) and 2 (Srebp2). The Srebp network 
which includes two genes and two intragenic miRNAs act 
synergistically to regulate cholesterol, triglyceride and lipid 
homeostasis.
While Srebp1 and miR-33b regulate lipid homeostasis 
and insulin signaling by modulating the activity of key 
genes involved in these processes, Srebp2 and its intronic 
miRNA, miR-33a, regulate cholesterol homeostasis by 
modulating transcriptionally and post-transcriptionally 
the activity of genes involved in the cellular cholesterol 
export, such as the ATP-binding cassette (ABC) transporter 
ABCA1 and ABCG1 (77-79). However, there is no 
specific separation of function made between miR-33a and 
miR-33b. The two miRNAs share overlapping gene targets 
through their similar mature sequence that differs only for 
two nucleotides. 
Inhibition of ABCA1 by miR-33 induced an efflux 
of cholesterol from peripheral tissues to the liver and 
a consequent reduction of circulating high-density 
lipoprotein-cholesterol (HDL-C) (78). In addition, this 
condition induced fatty acid degradation in human liver 
cells, through the lack of modulation in the expression of 
genes involved in the oxidation of fatty acid (77,80). MiR-33 
is also involved in the post-transcriptional modulation of 
other mRNAs that modulate lipid and glucose metabolism, 
such as the α1 subunit of AMP-activated protein kinase 
(AMPKα1) (77,81,82). 
Interestingly, miR33a has been found to interact with 
the 3'-utr region of c-Myc mRNA in breast cancer cell 
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lines (46). c-Myc is an important oncogene deregulated in 
several tumors. In particular, it is able to directly enhance 
the glycolytic pathway modulating the expression of lactate 
dehydrogenase A (LDHA), the enzyme that converts 
pyruvate to lactate (83), and promote mitochondrial 
biogenesis, hence increasing mitochondrial function (83,84). 
These aspects are important in generating substrates for 
macromolecular biosynthesis that guarantee rapid cell 
proliferation, which is a typical hallmark of cancer cells. 
The anticancer metabolic effects induced by metformin in 
breast cancer cell lines were, also, a direct consequence of the 
c-Myc inhibition mediated by the up regulation of miR-33a. 
Metformin was no longer able to induce metabolic changes 
in breast cancer cell lines over expressing c-Myc protein (46).
All these evidences have drawn researchers’ attention to 
studying the role that miRNAs play in the development of 
pathologies. This also highlights novel target therapies that 
can reverse either aberrant or loss of miRNA function.
MicroRNAs as mediators of the metformin 
anticancer activity
Growing evidence show that metformin can exert 
anticancer effects through miRNA modulation. It has 
recently been shown that metformin inhibited the growth 
of hepatocellular carcinoma by inducing G1 cell cycle 
arrest. This occurred through the aberrant modulation of 
miRNA expression (85). In addition, metformin treatment 
modulates differently the expression of miRNAs in human 
pancreatic cancer (86), esophageal squamous carcinoma (87), 
gastric cancer (88) and prostate cancer (89) .
In pancreatic cancer cell lines, metformin up-regulated 
the expression of miR-26a, miR-192 and let-7c (86). Over 
expression of miR-26a inhibited cell proliferation, invasion, 
migration and increased cell apoptosis through a direct 
modulation of HMGA1 (86) (Figure 2 and Table 1).
In A549 and NCI-H358 human lung cancer cell lines 
Figure 2 Metformin-induced microRNAs deregulation: schematic representation of the microRNAs and their mRNA targets modulated by 
metformin in both cancer and diabetic cell systems.
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metformin reduced the expression of miR-222, thus 
inhibiting cell growth and cell cycle progression via direct 
targeting of p27, p57 and PTEN, whose expression was up-
regulated in cells exposed to metformin (101) (Figure 2 and 
Table 1).
Metformin was also shown to significantly increase 
the number of senescence-prone murine embryonic 
fibroblasts (MEFs) entering a senescent stage in response to 
doxorubicin treatment. This might in part occur through 
metformin-induced modulation of the miRNAs 200 family 
and miR-205 (123) (Figure 2 and Table 1).
Recent evidences suggest that metformin impacts of the 
miRNA profile of type 2 diabetes patients.
The analysis of circulating miRNAs in plasma samples 
collected from type 2 diabetes and healthy individuals 
revealed a specific miRNAs profile linked to T2D. 
Interestingly plasma concentrations of four circulating 
miRNAs, miR-140-5p, miR-222, miR-142-3p and miR-
192 were significantly modulated by metformin, but not 
by placebo (124) (Figure 2 and Table 1). Coleman et al., 
performed a miRNA profiling of internal mammary artery 
segments collected from non-diabetic subjects, diabetic 
subjects treated with metformin (DMMet+), and diabetic 
subjects not treated with metformin (DMMet–). They 
found that the DMMet– group exhibited a significant 
increase in miR-221/222 which led to a decrease in p27 
mRNA compared to both the ND and DMMet+ groups. 
Vascular smooth muscle cells isolated from the internal 
mammary artery of the DMMet- group showed a high 
proliferation rate when compared to that of the ND and 
DMMet+ groups (125).
We reported that metformin modulated miRNA 
expression through the transcriptional modulation of Dicer 
in human breast cancer cell lines (Figure 2). Metformin 
was no longer able to affect tumor engraftment of breast 
cancer cells whose endogenous expression of DICER was 
selectively knocked-down (46). Low expression of DICER is 
correlated with a worst prognosis of breast, lung and ovarian 
cancer patients (126,127). Altogether these evidences 
indicate that the transcriptional axis including DICER and 
miRNAs could be one of molecular mechanisms underlying 
the anticancer effects exerted by metformin. 
Metformin was also shown to affect cancer stem 
cells (CSCs). It increased the cytotoxicity of many 
chemotherapeutic agents and prolonged tumor remission 
through its ability to selectively kill CSCs (8,128). 
Indeed, metformin sensitized breast cancer xenografts to 
doxorubicin treatment by targeting CD44+/CD24− CSCs–. 
This could potentially lead to a reduction in the dose of 
chemotherapy used and thereby reducing complications due 
to toxicity (8). 
Interestingly, Bao and colleagues  reported that pancreatic 
Table 1 microRNAs modulated by metformin and their more 
relevant known target genes in cancer 
microRNA
Known target in 
cancer
Reference
miR-140-5p ADAM10 Kai Y et al., 2014 (90)
TGFBR1; FGF9 Yang H et al., 2013 (91)
DNMT1 Takata A et al., 2013 (92)
HDAC4 Song B et al., 2009 (93)
miR-222 MGMT Quintavalle C et al., 2013 (94)
p27 le Sage C et al., 2007 (95)
ADIPOR1 Hwang MS et al., 2013 (96)
DKK2 Li Q et al., 2013 (97)
ADAM17 Xu K et al., 2012 (98)
PTPu Quintavalle C et al., 2012 (99)
PTEN, p57 Garofalo M et al., 2009 (100); 
Wang Y et al., 2013 (101)
miR-142-3p ADCY9 Huang B et al., 2009 (102)
miR-192 ZEB2 Wang B et al., 2010 (103)
Bcl2 VEGFA Geng L et al., 2013 (104)
let-7c RAS Johnson SM et al., 2005 (105)
TRIB2 Wang PY et al., 2013 (106)
Bcl-xL Cui SY et al., 2013 (107)
ITGB3 MAP4K3 Zhao B et al., 2014 (108)
MYC Nadiminty N et al., 2012 (109)
MMP11 PBX3 Han HB et al., 2012 (110)
miR-26a EZH2 Lu J et al., 2011 (111)
HMGA2 Palmieri D et al., 2012 (112)
miR-200 
family
ZEB1 Park SM et al., 2008 (113)
ZEB2 Gregory PA et al., 2008 (114)
SLUG Liu YN et al., 2013 (115)
E2F3 Feng B et al., 2012 (116)
SIRT1 Eades G et al., 2011 (117)
miR-205 LRP1 Song H, Bu G, 2009 (118)
ZEB1 ZEB2 Gregory PA et al., 2008 (114)
PTEN Greene SB et al., 2010 (119)
ERBB3 Wu H et al., 2009 (120)
miR-33a MYC Blandino et al., 2012 (46)
TWIST Zhou Y et al., 2014 (121)
PIM-1 Thomas M et al., 2012 (122)
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cell lines treated with metformin re-expressed several 
miRNAs usually switched off in pancreatic cancer, such as 
the miR-200 family of miRNA which plays a major role in 
epithelial to mesenchymal transition and in maintaining 
the stem cell state (129). They also showed that metformin 
inhibited tumor sphere formation by deregulating several 
CSC markers (CD44, EpCAM, EZH2, Notch-1, Nanog, and 
Oct4) partially through the up regulation of miRNAs (130).
We recently showed that metformin reprograms of 
ALDH bright cells. These represent a chemoresistant 
breast cancer cell subpopulation endowing tumor initiating 
cell properties. We demonstrated that metformin down-
regulates the c-MYC levels, possibly by up-regulating 
the mir-33a levels (131). Altogether these findings depict 
the close interplay between non-coding factors that exert 
a profound impact on the coding-derived proteins and 
reprogramming of cell metabolism.
Conclusions 
In the last decades an extraordinary amount of experimental 
work has been performed to uncover most of the messages 
contained in the coding genome. The recent advent of 
non-coding RNAs, of which miRNAs, among the diverse 
non-coding RNA populations represent that mostly 
investigated, adds a new layer of complexity toward the 
fully comprehension of the aberrant molecular mechanism 
underlying the diverse cancer hallmarks. In line with this, 
the fine deciphering of the anticancer metabolic effects 
exerted by metformin, at least partially, through the 
interplay with miRNAs might provide powerful insights 
to decode cancer metabolism. The principal aim is still to 
reprogram cancer metabolism toward that of untransformed 
cell through the re-wiring of the altered functional nodes. 
Much more experimental evidence is required to fulfill it, 
but the ongoing studies hold great promise.
Acknowledgements
We thank MIUR-FIRB (RBAP11LP2W, H81J10000030001) 
and Italian Health Office (TEVERE project) for generous 
support. We are grateful to Mrs Tania Merlino for 
proofreading the manuscript.
Disclosure: The authors declare no conflict of interest.
References
1. Parturier G, Hugnot G. Le galega dans le traitement du 
diabete. Paris: Massons, 1935.
2. Hundal RS, Krssak M, Dufour S, et al. Mechanism by 
which metformin reduces glucose production in type 2 
diabetes. Diabetes 2000;49:2063-9.
3. Lee JO, Lee SK, Jung JH, et al. Metformin Induces Rab4 
Through AMPK and Modulates GLUT4 Translocation 
in Skeletal Muscle Cells. Journal of Cellular Physiology 
2011;226:974-81.
4. Stephenne X, Foretz M, Taleux N, et al. Metformin 
activates AMP-activated protein kinase in primary 
human hepatocytes by decreasing cellular energy status. 
Diabetologia 2011;54:3101-10.
5. Evans JMM, Donnelly LA, Emslie-Smith AM, et al. 
Metformin and reduced risk of cancer in diabetic patients. 
British Medical Journal 2005;330:1304-5.
6. Bowker SL, Majumdar SR, Veugelers P, et al. Increased 
cancer-related mortality for patients with type 2 diabetes 
who use sulfonylureas or insulin - Response to Farooki and 
Schneider. Diabetes Care 2006;29:1990-1.
7. Menendez JA, Lupu R. Fatty acid synthase and the 
lipogenic phenotype in cancer pathogenesis. Nature 
Reviews Cancer 2007;7:763-77.
8. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin 
selectively targets cancer stem cells, and acts together 
with chemotherapy to block tumor growth and prolong 
remission. Cancer Res 2009;69:7507-11.
9. Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin 
inhibits growth and enhances radiation response of non-
small cell lung cancer (NSCLC) through ATM and 
AMPK. British Journal of Cancer 2013;108:2021-32.
10. Pulito C, Sanli T, Rana P, et al. Metformin: On Ongoing 
Journey across Diabetes, Cancer Therapy and Prevention. 
Metabolites 2013;3:1051-75.
11. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and 
molecular mechanisms of metformin: an overview. Clin Sci 
(Lond) 2012;122:253-70.
12. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic 
variation in the organic cation transporter 1 (OCT1) on 
metformin action. J Clin Invest 2007;117:1422-31.
13. Owen MR, Doran E, Halestrap AP. Evidence that 
metformin exerts its anti-diabetic effects through 
inhibition of complex 1 of the mitochondrial respiratory 
chain. Biochem J 2000;348 Pt 3:607-14.
14. El-Mir MY, Nogueira V, Fontaine E, et al. 
Dimethylbiguanide inhibits cell respiration via an indirect 
effect targeted on the respiratory chain complex I. J Biol 
Chem 2000;275:223-8.
15. Sanders MJ, Grondin PO, Hegarty BD, et al. Investigating 
Annals of Translational Medicine, Vol 2, No 6 June 2014 Page 9 of 13
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2014;2(6):58www.atmjournal.org
the mechanism for AMP activation of the AMP-activated 
protein kinase cascade. Biochem J 2007;403:139-48.
16. Xiao B, Heath R, Saiu P, et al. Structural basis for AMP 
binding to mammalian AMP-activated protein kinase. 
Nature 2007;449:496-500.
17. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 
mediates glucose homeostasis in liver and therapeutic 
effects of metformin. Science 2005;310:1642-6.
18. Hardie DG. The LKB1-AMPK Pathway-Friend or Foe in 
Cancer? Cancer Cell 2013;23:131-2.
19. Kalender A, Selvaraj A, Kim SY, et al. Metformin, 
independent of AMPK, inhibits mTORC1 in a rag 
GTPase-dependent manner. Cell Metab 2010;11:390-401.
20. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits 
hepatic gluconeogenesis in mice independently of the 
LKB1/AMPK pathway via a decrease in hepatic energy 
state. J Clin Invest 2010;120:2355-69.
21. Sun Y, Connors KE, Yang DQ. AICAR induces 
phosphorylation of AMPK in an ATM-dependent, LKB1-
independent manner. Mol Cell Biochem 2007;306:239-45.
22. Suzuki A, Kusakai G, Kishimoto A, et al. IGF-1 
phosphorylates AMPK-alpha subunit in ATM-dependent 
and LKB1-independent manner. Biochem Biophys Res 
Commun 2004;324:986-92.
23. Algire C, Amrein L, Bazile M, et al. Diet and tumor 
LKB1 expression interact to determine sensitivity to 
anti-neoplastic effects of metformin in vivo. Oncogene 
2011;30:1174-82.
24. Brunet J, Vazquez-Martin A, Colomer R, et al. BRCA1 
and acetyl-CoA carboxylase: the metabolic syndrome of 
breast cancer. Mol Carcinog 2008;47:157-63.
25. Alo’ PL, Visca P, Marci A, et al. Expression of fatty acid 
synthase (FAS) as a predictor of recurrence in stage I breast 
carcinoma patients. Cancer 1996;77:474-82.
26. Visca P, Sebastiani V, Botti C, et al. Fatty acid synthase 
(FAS) is a marker of increased risk of recurrence in lung 
carcinoma. Anticancer Res 2004;24:4169-73.
27. Sebastiani V, Visca P, Botti C, et al. Fatty acid synthase is 
a marker of increased risk of recurrence in endometrial 
carcinoma. Gynecol Oncol 2004;92:101-5.
28. Alò PL, Visca P, Trombetta G, et al. Fatty acid synthase 
(FAS) predictive strength in poorly differentiated early 
breast carcinomas. Tumori 1999;85:35-40.
29. Gansler TS, Hardman W, 3rd, Hunt DA, et al. Increased 
expression of fatty acid synthase (OA-519) in ovarian 
neoplasms predicts shorter survival. Hum Pathol 
1997;28:686-92.
30. Cantoria MJ, Boros LG, Meuillet EJ. Contextual 
inhibition of fatty acid synthesis by metformin involves 
glucose-derived acetyl-CoA and cholesterol in pancreatic 
tumor cells. Metabolomics 2014;10:91-104.
31. Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin 
inhibits mammalian target of rapamycin-dependent 
translation initiation in breast cancer cells. Cancer Res 
2007;67:10804-12.
32. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK 
phosphorylation of raptor mediates a metabolic 
checkpoint. Mol Cell 2008;30:214-26.
33. Inoki K, Corradetti MN, Guan KL. Dysregulation of 
the TSC-mTOR pathway in human disease. Nat Genet 
2005;37:19-24.
34. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular 
energy response to control cell growth and survival. Cell 
2003;115:577-90.
35. Woodard J, Joshi S, Viollet B, et al. AMPK as a therapeutic 
target in renal cell carcinoma. Cancer Biol Ther 
2010;10:1168-77.
36. Zhang T, Guo P, Zhang Y, et al. The antidiabetic drug 
metformin inhibits the proliferation of bladder cancer cells 
in vitro and in vivo. Int J Mol Sci 2013;14:24603-18.
37. Checkley LA, Rho O, Angel JM, et al. Metformin inhibits 
skin tumor promotion in overweight and obese mice. 
Cancer Prev Res (Phila) 2014;7:54-64.
38. Quattrini I, Conti A, Pazzaglia L, et al. Metformin inhibits 
growth and sensitizes osteosarcoma cell lines to cisplatin 
through cell cycle modulation. Oncol Rep 2014;31:370-5.
39. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic 
treatment with the antidiabetic drug metformin selectively 
impairs p53-deficient tumor cell growth. Cancer Res 
2007;67:6745-52.
40. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein 
kinase induces a p53-dependent metabolic checkpoint. 
Mol Cell 2005;18:283-93.
41. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of 
p53 function and stability by phosphorylation. Mol Cell 
Biol 1999;19:1751-8.
42. Chao C, Saito S, Anderson CW, et al. Phosphorylation of 
murine p53 at ser-18 regulates the p53 responses to DNA 
damage. Proc Natl Acad Sci U S A 2000;97:11936-41.
43. He G, Zhang YW, Lee JH, et al. AMP-activated protein 
kinase induces p53 by phosphorylating MDMX and 
inhibiting its activity. Mol Cell Biol 2014;34:148-57.
44. Cerezo M, Tichet M, Abbe P, et al. Metformin Blocks 
Melanoma Invasion and Metastasis Development in 
AMPK/p53-Dependent Manner. Mol Cancer Ther 
2013;12:1605-15.
Pulito et al. microRNAs and metformin
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2014;2(6):58www.atmjournal.org
Page 10 of 13
45. Akinyeke T, Matsumura S, Wang X, et al. Metformin 
targets c-MYC oncogene to prevent prostate cancer. 
Carcinogenesis 2013;34:2823-32.
46. Blandino G, Valerio M, Cioce M, et al. Metformin elicits 
anticancer effects through the sequential modulation of 
DICER and c-MYC. Nat Commun 2012;3:865.
47. Dallaglio K, Bruno A, Cantelmo AR, et al. Paradoxic 
effects of metformin on endothelial cells and angiogenesis. 
Carcinogenesis 2014;35:1055-66.
48. Samarajeewa NU, Ham S, Yang F, et al. Promoter-specific 
effects of metformin on aromatase transcript expression. 
Steroids 2011;76:768-71.
49. Memmott RM, Mercado JR, Maier CR, et al. Metformin 
prevents tobacco carcinogen--induced lung tumorigenesis. 
Cancer Prev Res (Phila) 2010;3:1066-76.
50. Würth R, Pattarozzi A, Gatti M, et al. Metformin 
selectively affects human glioblastoma tumor-initiating cell 
viability: A role for metformin-induced inhibition of Akt. 
Cell Cycle 2013;12:145-56.
51. Liu X, Chhipa RR, Pooya S, et al. Discrete mechanisms 
of mTOR and cell cycle regulation by AMPK agonists 
independent of AMPK. Proc Natl Acad Sci U S A 
2014;111:E435-44.
52. Adashi EY. The IGF family and folliculogenesis. J Reprod 
Immunol 1998;39:13-9.
53. Smith MR, Lee H, Nathan DM. Insulin sensitivity during 
combined androgen blockade for prostate cancer. J Clin 
Endocrinol Metab 2006;91:1305-8.
54. Warshamana-Greene GS, Litz J, Buchdunger E, et al. 
The insulin-like growth factor-I receptor kinase inhibitor, 
NVP-ADW742, sensitizes small cell lung cancer cell 
lines to the effects of chemotherapy. Clin Cancer Res 
2005;11:1563-71.
55. Quinn BJ, Dallos M, Kitagawa H, et al. Inhibition of lung 
tumorigenesis by metformin is associated with decreased 
plasma igf-I and diminished receptor tyrosine kinase 
signaling. Cancer Prev Res (Phila) 2013;6:801-10.
56. Arai M, Uchiba M, Komura H, et al. Metformin, an 
antidiabetic agent, suppresses the production of tumor 
necrosis factor and tissue factor by inhibiting early growth 
response factor-1 expression in human monocytes in vitro. 
J Pharmacol Exp Ther 2010;334:206-13.
57. Algire C, Moiseeva O, Deschenes-Simard X, et al. 
Metformin reduces endogenous reactive oxygen species 
and associated DNA damage. Cancer Prev Res (Phila) 
2012;5:536-43.
58. Menendez JA, Cufi S, Oliveras-Ferraros C, et al. 
Metformin and the ATM DNA damage response (DDR): 
accelerating the onset of stress-induced senescence to 
boost protection against cancer. Aging (Albany NY) 
2011;3:1063-77.
59. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, et al. 
Metformin activates an ataxia telangiectasia mutated 
(ATM)/Chk2-regulated DNA damage-like response. Cell 
Cycle 2011;10:1499-501.
60. Do MT, Kim HG, Khanal T, et al. Metformin inhibits 
heme oxygenase-1 expression in cancer cells through 
inactivation of Raf-ERK-Nrf2 signaling and AMPK-
independent pathways. Toxicol Appl Pharmacol 
2013;271:229-38.
61. Ma Y, Guo FC, Wang W, et al. K-ras gene mutation as a 
predictor of cancer cell responsiveness to metformin. Mol 
Med Rep 2013;8:763-8.
62. Bartel DP. MicroRNAs: Genomics, biogenesis, 
mechanism, and function. Cell 2004;116:281-97.
63. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. 
Identification of novel genes coding for small expressed 
RNAs. Science 2001;294:853-8.
64. Lagos-Quintana M, Rauhut R, Meyer J, et al. New 
microRNAs from mouse and human. RNA 2003;9:175-9.
65. Lau NC, Lim LP, Weinstein EG, et al. An abundant 
class of tiny RNAs with probable regulatory roles in 
Caenorhabditis elegans. Science 2001;294:858-62.
66. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs 
in animals. Nature Reviews Molecular Cell Biology 
2009;10:126-39.
67. Lee Y, Kim M, Han JJ, et al. MicroRNA genes are 
transcribed by RNA polymerase II. Embo Journal 
2004;23:4051-60.
68. Han J, Lee Y, Yeom KH, et al. Molecular basis for the 
recognition of primary microRNAs by the Drosha-
DGCR8 complex. Cell 2006;125:887-901.
69. Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the 
nuclear export of pre-microRNAs and short hairpin RNAs. 
Genes & Development 2003;17:3011-6.
70. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a 
RanGTP-dependent dsRNA-binding protein that mediates 
nuclear export of pre-miRNAs. RNA 2004;10:185-91.
71. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. 
TRBP recruits the Dicer complex to Ago2 for microRNA 
processing and gene silencing. Nature 2005;436:740-4.
72. Gregory RI, Chendrimada TP, Cooch N, et al. 
Human RISC couples microRNA biogenesis and 
posttranscriptional gene silencing. Cell 2005;123:631-40.
73. Pasquinelli AE. NON-CODING RNA MicroRNAs and 
their targets: recognition, regulation and an emerging 
Annals of Translational Medicine, Vol 2, No 6 June 2014 Page 11 of 13
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2014;2(6):58www.atmjournal.org
reciprocal relationship. Nature Reviews Genetics 
2012;13:271-82.
74. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: 
diagnostics, monitoring and therapeutics. A comprehensive 
review. Embo Molecular Medicine 2012;4:143-59.
75. Esau C, Davis S, Murray SF, et al. miR-122 regulation of 
lipid metabolism revealed by in vivo antisense targeting. 
Cell Metab 2006;3:87-98.
76. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing 
of microRNAs in vivo with ‘antagomirs’. Nature 
2005;438:685-9.
77. Dávalos A, Goedeke L, Smibert P, et al. miR-33a/b 
contribute to the regulation of fatty acid metabolism 
and insulin signaling. Proc Natl Acad Sci U S A 
2011;108:9232-7.
78. Marquart TJ, Allen RM, Ory DS, et al. miR-33 links 
SREBP-2 induction to repression of sterol transporters. 
Proc Natl Acad Sci U S A 2010;107:12228-32.
79. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 
and the SREBP host genes cooperate to control cholesterol 
homeostasis. Science 2010;328:1566-9.
80. Gerin I, Clerbaux LA, Haumont O, et al. Expression of 
miR-33 from an SREBP2 intron inhibits cholesterol export 
and fatty acid oxidation. J Biol Chem 2010;285:33652-61.
81. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of 
miR-33a/b in non-human primates raises plasma HDL 
and lowers VLDL triglycerides. Nature 2011;478:404-7.
82. Rottiers V, Najafi-Shoushtari SH, Kristo F, et al. 
MicroRNAs in metabolism and metabolic diseases. Cold 
Spring Harb Symp Quant Biol 2011;76:225-33.
83. Lewis BC, Shim H, Li Q, et al. Identification of putative 
c-Myc-responsive genes: characterization of rcl, a novel 
growth-related gene. Mol Cell Biol 1997;17:4967-78.
84. Menssen A, Hermeking H. Characterization of the 
c-MYC-regulated transcriptome by SAGE: identification 
and analysis of c-MYC target genes. Proc Natl Acad Sci U 
S A 2002;99:6274-9.
85. Miyoshi H, Kato K, Iwama H, et al. Effect of the anti-
diabetic drug metformin in hepatocellular carcinoma in 
vitro and in vivo. Int J Oncol 2013. [Epub ahead of print].
86. Li W, Yuan Y, Huang L, et al. Metformin alters the 
expression profiles of microRNAs in human pancreatic 
cancer cells. Diabetes Res Clin Pract 2012;96:187-95.
87. Kobayashi M, Kato K, Iwama H, et al. Antitumor effect of 
metformin in esophageal cancer: in vitro study. Int J Oncol 
2013;42:517-24.
88. Kato K, Gong J, Iwama H, et al. The antidiabetic drug 
metformin inhibits gastric cancer cell proliferation in vitro 
and in vivo. Mol Cancer Ther 2012;11:549-60.
89. Avci CB, Harman E, Dodurga Y, et al. Therapeutic 
potential of an anti-diabetic drug, metformin: alteration 
of miRNA expression in prostate cancer cells. Asian Pac J 
Cancer Prev 2013;14:765-8.
90. Kai Y, Peng W, Ling W, et al. Reciprocal effects between 
microRNA-140-5p and ADAM10 suppress migration and 
invasion of human tongue cancer cells. Biochem Biophys 
Res Commun 2014;448:308-14.
91. Yang H, Fang F, Chang R, et al. MicroRNA-140-5p 
suppresses tumor growth and metastasis by targeting 
transforming growth factor beta receptor 1 and fibroblast 
growth factor 9 in hepatocellular carcinoma. Hepatology 
2013;58:205-17.
92. Takata A, Otsuka M, Yoshikawa T, et al. MicroRNA-140 
acts as a liver tumor suppressor by controlling NF-kappaB 
activity by directly targeting DNA methyltransferase 1 
(Dnmt1) expression. Hepatology 2013;57:162-70.
93. Song B, Wang Y, Xi Y, et al. Mechanism of 
chemoresistance mediated by miR-140 in human 
osteosarcoma and colon cancer cells. Oncogene 
2009;28:4065-74.
94. Quintavalle C, Mangani D, Roscigno G, et al. MiR-
221/222 target the DNA methyltransferase MGMT in 
glioma cells. PLoS One 2013;8:e74466.
95. le Sage C, Nagel R, Egan DA, et al. Regulation of the 
p27(Kip1) tumor suppressor by miR-221 and miR-
222 promotes cancer cell proliferation. EMBO J 
2007;26:3699-708.
96. Hwang MS, Yu N, Stinson SY, et al. miR-221/222 
targets adiponectin receptor 1 to promote the epithelial-
to-mesenchymal transition in breast cancer. PLoS One 
2013;8:e66502.
97. Li Q, Shen K, Zhao Y, et al. MicroRNA-222 promotes 
tumorigenesis via targeting DKK2 and activating 
the Wnt/beta-catenin signaling pathway. FEBS Lett 
2013;587:1742-8.
98. Xu K, Liang X, Shen K, et al. MiR-222 modulates 
multidrug resistance in human colorectal carcinoma 
by down-regulating ADAM-17. Exp Cell Res 
2012;318:2168-77.
99. Quintavalle C, Garofalo M, Zanca C, et al. miR-
221/222 overexpession in human glioblastoma increases 
invasiveness by targeting the protein phosphate PTPmu. 
Oncogene 2012;31:858-68.
100. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 
Regulate TRAIL Resistance and Enhance Tumorigenicity 
through PTEN and TIMP3 Downregulation. Cancer Cell 
Pulito et al. microRNAs and metformin
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2014;2(6):58www.atmjournal.org
Page 12 of 13
2009;16:498-509.
101. Wang Y, Dai W, Chu X, et al. Metformin inhibits lung 
cancer cells proliferation through repressing microRNA-222. 
Biotechnol Lett 2013;35:2013-9.
102. Huang B, Zhao J, Lei Z, et al. miR-142-3p restricts cAMP 
production in CD4+CD25- T cells and CD4+CD25+ 
TREG cells by targeting AC9 mRNA. EMBO Rep 
2009;10:180-5.
103. Wang B, Herman-Edelstein M, Koh P, et al. 
E-cadherin expression is regulated by miR-192/215 
by a mechanism that is independent of the profibrotic 
effects of transforming growth factor-beta. Diabetes 
2010;59:1794-802.
104. Geng L, Chaudhuri A, Talmon G, et al. MicroRNA-192 
suppresses liver metastasis of colon cancer. Oncogene 
2013. [Epub ahead of print].
105. Johnson SM, Grosshans H, Shingara J, et al. RAS 
is regulated by the let-7 microRNA family. Cell 
2005;120:635-47.
106. Wang PY, Sun YX, Zhang S, et al. Let-7c inhibits A549 
cell proliferation through oncogenic TRIB2 related 
factors. FEBS Lett 2013;587:2675-81.
107. Cui SY, Huang JY, Chen YT, et al. Let-7c governs the 
acquisition of chemo- or radioresistance and epithelial-to-
mesenchymal transition phenotypes in docetaxel-resistant 
lung adenocarcinoma. Mol Cancer Res 2013;11:699-713.
108. Zhao B, Han H, Chen J, et al. MicroRNA let-7c inhibits 
migration and invasion of human non-small cell lung 
cancer by targeting ITGB3 and MAP4K3. Cancer Lett 
2014;342:43-51.
109. Nadiminty N, Tummala R, Lou W, et al. MicroRNA let-
7c suppresses androgen receptor expression and activity 
via regulation of Myc expression in prostate cancer cells. J 
Biol Chem 2012;287:1527-37.
110. Han HB, Gu J, Zuo HJ, et al. Let-7c functions as a 
metastasis suppressor by targeting MMP11 and PBX3 in 
colorectal cancer. J Pathol 2012;226:544-55.
111. Lu J, He ML, Wang L, et al. MiR-26a inhibits cell growth 
and tumorigenesis of nasopharyngeal carcinoma through 
repression of EZH2. Cancer Res 2011;71:225-33.
112. Palmieri D, D’Angelo D, Valentino T, et al. 
Downregulation of HMGA-targeting microRNAs has a 
critical role in human pituitary tumorigenesis. Oncogene 
2012;31:3857-65.
113. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family 
determines the epithelial phenotype of cancer cells by 
targeting the E-cadherin repressors ZEB1 and ZEB2. 
Genes Dev 2008;22:894-907.
114. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 
family and miR-205 regulate epithelial to mesenchymal 
transition by targeting ZEB1 and SIP1. Nat Cell Biol 
2008;10:593-601.
115. Liu YN, Yin JJ, Abou-Kheir W, et al. MiR-1 and miR-
200 inhibit EMT via Slug-dependent and tumorigenesis 
via Slug-independent mechanisms. Oncogene 
2013;32:296-306.
116. Feng B, Wang R, Song HZ, et al. MicroRNA-200b 
reverses chemoresistance of docetaxel-resistant human 
lung adenocarcinoma cells by targeting E2F3. Cancer 
2012;118:3365-76.
117. Eades G, Yao Y, Yang M, et al. miR-200a regulates SIRT1 
expression and epithelial to mesenchymal transition 
(EMT)-like transformation in mammary epithelial cells. J 
Biol Chem 2011;286:25992-6002.
118. Song H, Bu G. MicroRNA-205 inhibits tumor cell 
migration through down-regulating the expression of the 
LDL receptor-related protein 1. Biochem Biophys Res 
Commun 2009;388:400-5.
119. Greene SB, Herschkowitz JI, Rosen JM. The ups and 
downs of miR-205: identifying the roles of miR-205 in 
mammary gland development and breast cancer. RNA Biol 
2010;7:300-4.
120. Wu H, Zhu S, Mo YY. Suppression of cell growth 
and invasion by miR-205 in breast cancer. Cell Res 
2009;19:439-48.
121. Zhou Y, Huang Z, Wu S, et al. miR-33a is up-regulated in 
chemoresistant osteosarcoma and promotes osteosarcoma 
cell resistance to cisplatin by down-regulating TWIST. J 
Exp Clin Cancer Res 2014;33:12.
122. Thomas M, Lange-Grunweller K, Weirauch U, et al. The 
proto-oncogene Pim-1 is a target of miR-33a. Oncogene 
2012;31:918-28.
123. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et 
al. Metformin lowers the threshold for stress-induced 
senescence: a role for the microRNA-200 family and miR-
205. Cell Cycle 2012;11:1235-46.
124. Ortega FJ, Mercader JM, Moreno-Navarrete JM, et al. 
Profiling of Circulating MicroRNAs Reveals Common 
MicroRNAs Linked to Type 2 Diabetes That Change 
With Insulin Sensitization. Diabetes Care 2014.
125. Coleman CB, Lightell DJ Jr, Moss SC, et al. Elevation 
of miR-221 and -222 in the internal mammary arteries of 
diabetic subjects and normalization with metformin. Mol 
Cell Endocrinol 2013;374:125-9.
126. Karube Y, Tanaka H, Osada H, et al. Reduced expression 
of Dicer associated with poor prognosis in lung cancer 
Annals of Translational Medicine, Vol 2, No 6 June 2014 Page 13 of 13
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2014;2(6):58www.atmjournal.org
Cite this article as: Pulito C, Donzelli S, Muti P, Puzzo L, 
Strano S, Blandino G. microRNAs and cancer metabolism 
reprogramming: the paradigm of metformin. Ann Transl Med 
2014;2(6):58. doi: 10.3978/j.issn.2305-5839.2014.06.03
patients. Cancer Sci 2005;96:111-5.
127. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and 
outcomes in patients with ovarian cancer. N Engl J Med 
2008;359:2641-50.
128. Ning X, Shu J, Du Y, et al. Therapeutic strategies targeting 
cancer stem cells. Cancer Biol Ther 2013;14:295-303.
129. Bao B, Wang Z, Ali S, et al. Metformin inhibits cell 
proliferation, migration and invasion by attenuating CSC 
function mediated by deregulating miRNAs in pancreatic 
cancer cells. Cancer Prev Res (Phila) 2012;5:355-64.
130. Wellner U, Schubert J, Burk UC, et al. The EMT-
activator ZEB1 promotes tumorigenicity by repressing 
stemness-inhibiting microRNAs. Nat Cell Biol 
2009;11:1487-95. 
131. Cioce M, Valerio M, Casadei L, et al. Metformin-induced 
metabolic reprogramming of chemoresistant ALDH bright 
breast cancer cells. Oncotarget, 2014. Available online: http://
www.impactjournals.com/oncotarget/index.php?journal=onc
otarget&page=article&op=view&path%5B%5D=1864
